Generics Bulletin is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ASBM Hits Back At British Columbia Switching Scheme

Executive Summary

Originator-backed lobbying group the Alliance for Safe Biologic Medicines has raised concerns over a biosimilar switching policy recently unveiled by the Canadian province of British Columbia.


Related Content

Canadian Pharmacare Report Urges Mandatory Substitution
England Expects Biosimilar Savings Of Up To Half A Billion
British Columbia Starts Biosimilar Switching Program
UK expects to save 75% from adalimumab rivals





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts